Drug Type Synthetic peptide, Biosimilar |
Synonyms Semaglutide Biosimilar (Pepgene Co. Ltd.), 司美格鲁肽 生物类似药(Pepgene Co. Ltd.), PG-004 (Pepgene) + [1] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Preclinical | South Korea | 18 Sep 2024 | |
Obesity | Preclinical | South Korea | 18 Sep 2024 |